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1106Objectives: Cardiac transplantation and available mechanical alternatives are the only possible solutions for
end-stage cardiac disease. Unfortunately, because of the limited supply of human organs, xenotransplantation
may be the ideal method to overcome this shortage. We have recently seen significant prolongation of hetero-
topic cardiac xenograft survival from 3 to 12 months and beyond.
Methods:Hearts from genetically engineered piglets that were alpha 1-3 galactosidase transferase knockout and
expressed the human complement regulatory gene, CD46 (groups A-C), and the human thrombomodulin gene
(group D) were heterotropically transplanted in baboons treated with antithymocyte globulin, cobra venom fac-
tor, anti-CD20 antibody, and costimulation blockade (anti-CD154 antibody [clone 5C8]) in group A, anti-CD40
antibody (clone 3A8; 20 mg/kg) in group B, clone 2C10R4 (25 mg/kg) in group C, or clone 2C10R4 (50 mg/kg)
in group D, along with conventional nonspecific immunosuppressive agents.
Results: Group A grafts (n¼ 8) survived for an average of 70 days, with the longest survival of 236 days. Some
animals in this group (n ¼ 3) developed microvascular thrombosis due to platelet activation and consumption,
which resulted in spontaneous hemorrhage. The median survival time was 21 days in group B (n¼ 3), 80 days in
group C (n ¼ 6), and more than 200 days in group D (n ¼ 5). Three grafts in group D are still contracting well,
with the longest ongoing graft survival surpassing the 1-year mark.
Conclusions: Genetically engineered pig hearts (GTKOhTg.hCD46.hTBM) with modified targeted immuno-
suppression (anti-CD40 monoclonal antibody) achieved long-term cardiac xenograft survival. This potentially
paves the way for clinical xenotransplantation if similar survival can be reproduced in an orthotopic transplan-
tation model. (J Thorac Cardiovasc Surg 2014;148:1106-14)Patients with end-stage organ failure waiting for donor
organs have limited treatment options. For those with car-
diac failure, mechanical assist devices provide one solu-
tion, but various complications associated with these
devices have reduced their effectiveness.1 Until we learn
to grow organs via tissue engineering, which is unlikely
in the near future, xenotransplantation seems to be a valid
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The Journal of Thoracic and Cardiovascular Surmany setbacks over the years, 2 major recent developments
have helped revitalized progress in the xenotransplantation
field. First is the ability to produce genetically engineered
(GE) pigs2,3 in which certain genes that are immunogenic
to humans are knocked out and human transgenes, such
as complement regulatory proteins (human complement
regulatory protein) and human thromboregulatory
protein, are expressed on pig cells.4 The second
achievement is the development of target-specific
immunosuppression that could be used clinically in
place of generalized immunosuppression.4 With these
developments, cardiac xenograft survival has been
prolonged to more than 1 year.5 Because of the cost of
these experiments and scarce research funding, it is not
feasible to address each genetic and immunosuppressive
manipulation individually. Therefore, laboratories per-
forming experiments in the field of xenotransplantation
have selectively picked specific genetic modifications in
pigs and immunosuppressive drug combinations to
perform xenotransplantation experiments. In this report,
we have summarized our results from multiple
experiments to show the impact of these GE pigs and
target-specific immune suppression focusing on recipient
B-cell depletion and costimulation blockade.gery c September 2014
Abbreviations and Acronyms
ACT ¼ activated clotting time
CMV ¼ cytomegalovirus
EKG ¼ electrocardiogram
GE ¼ genetically engineered
Ig ¼ immunoglobulin
IV ¼ intravenously
LVP ¼ left ventricular pressure
mAb ¼ monoclonal antibody
SPF ¼ specific pathogen-free
TBM ¼ thrombomodulin
TM ¼ thrombotic microangiopathy
WBC ¼ white blood cell
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Animal Models and Genetic Modifications
Specific pathogen-free (SPF) baboons weighing 7 to 15 kg from the
University of Oklahoma (Norman, Okla) were housed in a clean
pathogen-free facility. These SPF baboons are known to have lower levels
of both anti–non-Gal immunoglobulin (Ig)G and IgM.6,7 Genetically
modified pigs (aged 4-8 weeks) that were alpha galactosidase transferase
knockout and hCD46 transgenic (GTKO.hCD46), with or without
thrombomodulin (TBM) expression (Revivicor Inc, Blacksburg, Va),
were used as heart donors. The weights of donor pigs were matched to
the baboon recipient to ensure adequate accommodation of the
heterotopic heart. All animals were used in compliance with guidelines
provided by the National Heart, Lung, and Blood Institute Animal Care
and Use Committee. All transplant procedures were performed at a
National Heart, Lung, and Blood Institute core surgical facility.Surgical Procedure
Donor pig hearts were transplanted into recipient SPF baboons in a
heterotopic position, as described previously.8 Briefly, the recipient
baboon’s infrarenal aorta and inferior vena cava were exposed through a
midline abdominal incision. Side-biting clamps were applied; an
aortotomy and venotomy were made, and the end-to-side anastomosis
was performed between the donor and recipient aorta and the donor
pulmonary artery with the recipient inferior vena cava.T
XImmunosuppressive Regimen
A detailed description of the immunosuppressive regimen is shown in
Figure 1. In brief, it includes induction with antithymocyte globulin,
anti-CD20 antibody (Rituxan; Genentech, Inc, South San Francisco,
Calif), and costimulation blockade with anti-CD154 (5C8) or anti-CD40
(3A8 or 2C10R4) monoclonal antibody (mAb). Cobra venom factor was
used to inhibit the complement activation. Mycophenolate mofetil and
costimulation blockade antibody were also used daily and weekly as
described in Figure 1 to prevent immune rejection. All recipient baboons
received continuous heparin infusion to maintain the activated clotting
time (ACT) level at twice the baseline. Ganciclovir was administered intra-
venously (IV) daily to prevent any potential viral infections. Erythropoietin
(200 U/kg) was administered IV daily from day 7 to 7, and cefazolin
(250 mg) IV was administered twice per day for 7 days.
Experimental Groups
The experimental groups are described in Table 1, and the duration of
immunosuppression is illustrated in Figure 1. The main difference amongThe Journal of Thoracic and Carthe 4 groups was the type, strength, and duration of antibody used for
costimulation blockade. In group A, anti-CD154 (5C8) (20 mg/kg) IV
was used for the entire period of graft survival. In group B, anti-CD40
(3A8) (20 mg/kg) IV was used for a maximum of 60 days. In group C,
anti-CD40 (2C10) (20 mg/kg) was tapered off in 60 days. In group D,
anti-CD40 (2C10) (50 mg/kg) was continued for 1 year (n ¼ 2) or reduced
(25 mg/kg) after 100 days (n ¼ 2).
Rescue Therapy
If rejection was suspected by diminution of xenograft function,
rescue therapy was initiated with intravenous methyl prednisolone (10-
15 mg/kg) for 6 days. Heparin was also used to prevent thrombus forma-
tion, and activated clotted time (ACT)wasmaintained at twice the baseline.
Measurement of Graft Survival
Telemetry, manual palpation, and noninvasive ultrasonography were
used to monitor the xenograft function. A telemetry device was implanted
at the time of transplantation to monitor the baboon recipient’s tempera-
ture, graft left ventricular pressure (LVP), and electrocardiogram (EKG).
The telemetry device data were transmitted wirelessly to a receiver
attached to the animal’s cage (RMISS, Wilmington, Del). The parameters
were recorded and included the peak systolic pressure, end-diastolic pres-
sure, LVP, heart rate based on LVP, EKG, heart rate based on EKG, and re-
cipient’s body temperature. Heart function was continuously evaluated by
telemetry, and a decrease in LVP to less than 60mmHgwas correlated with
the initiation of the rejection process, which affected the graft contractility.
An LVP less than 10mmHgwas an indicator of complete cessation of graft
contractility.
Recipients were sedated weekly for the first 2 months post-transplant
and biweekly thereafter for blood collection. Palpation and ultrasound
were also done on this schedule. On the basis of xenograft palpation,
contractility of the heart was scored as þþþþ (fully functional) to
0 (nonfunctional). Blood flow and wall motion were analyzed by
echocardiography.
Hematology
White blood cell (WBC) count, hematocrit, red blood cell count, hemo-
globin, platelets, neutrophils, and monocytes were analyzed. Blood chem-
istry was performed weekly for the first 2 months and then biweekly until
the graft was explanted or rejected. ACT, prothrombin time, and troponin
levels were measured at the same intervals.
Histology
Paraffin sections from biopsies and explanted xenografts were stained
with hematoxylin–eosin for light microscopy. Sections were analyzed for
cardiomyocyte viability and the presence of hemorrhage, microvasculature
thrombosis, and cellular infiltrates.RESULTS
Graft Survival
Graft survival curves for all groups are shown in Figure 2,
A. Median graft survivals of the 4 groups are shown in
Figure 2, B, and the longest survival in each group is shown
in Figure 2, C. Among all groups, group D, receiving the
high dose of anti-CD40mAb, had the longest median and in-
dividual survival. In group A, most of the grafts were still
contracting at the time of recipient death or euthanasia
because of various complications. All grafts in groups B
and C were rejected. Two of 5 grafts in group D stopped
contracting on postoperative days 146 and 159, but the otherdiovascular Surgery c Volume 148, Number 3 1107
FIGURE 1. Timeline of various immunosuppressive drugs: The red stop sign indicates that the drug was stopped at this point. The duration of antibody
treatment in 4 different groups is shown. Antibody in groups A and Dwas given until the graft was rejected or explanted. ATG, Antithymocyte globulin; BID,
twice per day; CVF, cobra venom factor; MMF, mycophenolate mofetil.
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X3 grafts are still contracting at more than 200 to 500 days at
the time of this submission.Measurement of Graft Contractility
Echocardiography was performed only in groups C and D
(echocardiography machine not available for earlier exper-
iments) receiving 2C10R4mAb and GTKO.hCD46 (group
C) or GTKO.hCD46.hTBM (group D) pig heart xenografts.
Excellent graft contractility was observed in all animals.
The original wall thickness was maintained to the end,
but in animals that stopped functioning in both groups,
left ventricular and left atrial walls were considerably thick-
ened. Of note, there was no thrombus observed in group D
receiving grafts with human TBM expression and high-dose
anti-CD40 mAb (2C10R4) treatment.
Telemetry was used to measure LVP and EKG. The heart
rate was calculated by the software on the basis of theTABLE 1. Description of the 4 experimental groups: The difference in
costimulation blockade and B-cell depletion in each group
Group Pig genetics n
A GTKO.hCD46Tg 8
B GTKO.hCD46Tg 3
C GTKO.hCD46Tg 6
D GTKO.hCD46Tg.hTBM 5
1108 The Journal of Thoracic and Cardiovascular Surnumber of LVP peaks and QRS complexes per minute.
Because of limited battery life, telemetry was useful for
200 to 400 days post-transplantation. Three grafts in group
D were still functioning to the day of the submission of the
article, and telemetry was useful in determining graft func-
tion for 230, 250, and 400 days in each. All of the grafts in
group C rejected within 146 days, and telemetry docu-
mented a loss of LVP and heart contractility. Manual graft
palpation scores were consistent with the findings of ultra-
sound and telemetry.Depletion of Tand B Cells and the Effect on Non-Gal
Antibody Production
Initial treatment with ATG significantly reduced the
number of circulating T cells, but they were not totally elim-
inated. However, treatment with 4 weekly doses of anti-
CD20 effectively depleted all of the circulating B cells,the 4 experimental groups is described, including the antibody for
Costimulation blockade B-cell depletion
Anti-CD154 (5C8) Anti-CD20
Anti-CD40 (3A8) Anti-CD20
Anti-CD40 (2C10R4) Low dose Anti-CD20
Anti-CD40 (2C10R4) High dose Anti-CD20
gery c September 2014
FIGURE 2. Graft survival: A, Survival days for grafts in all groups are shown. B, Median survival time of xenografts in each group is shown. C, Longest
survival time in each group is shown.
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Xand they stayed depleted for at least 60 days, after which
they were slowly restored to pretreatment levels.6,9
Although anti-CD20 has no direct affect on plasma cells,
the non-Gal antibody production was maintained at a low
level by this treatment.
Complete Blood Count, Chemistry, and Coagulation
Profile
Figure 3 shows the comparison of WBC count, platelet
count, hematocrit, and hemoglobin levels. The treatment
regimen was effective in keeping WBC counts low in all
4 groups. The median platelet numbers were maintained
better with 2C10R4 mAb treatment, but only group C
platelet counts were significantly better than in the other 3
groups. The hemoglobin level and hematocrit percentage
were kept close to normal in all groups, and there was no
significant difference among the groups. Anemia and
thrombocytopenia were treated with a transfusion of packed
red blood cells as needed.
Graft Histology
Graft histology in group A showed small areas of normal
myocardium along with significant areas of hemorrhage,
coagulative necrosis, and fibrosis. Some thrombotic micro-
angiopathy (TM) was observed in this group. No TM was
observed in groups B, C, or D. Rejected grafts in groups
B, C, and D showed some myofibril loss with fibrosis, but
there was only minimal hemorrhage present. Figure 4 shows
a representative hematoxylin–eosin staining of a left
ventricle from the group A graft, showing widespread areas
of fibrosis, along with some normal myocytes, and a biopsy
specimen from a group D heart taken at 182 days postoper-
atively, showing primarily normal myocytes and a small
area of fibrosis.
Complications
Most animals in group A had to be euthanized or died of
various complications (eg, abdominal bleeding, aspiration
pneumonia, and consumptive coagulopathy). Infections
were rare in all the groups and if noticed were managed
by antibiotic treatment after culture and sensitivity testing
was performed. Few complications were seen in groups
B, C, and D. In these groups, most of the heart xenografts
were explanted after rejection, and recipient baboons
survived.
DISCUSSION
The availability of GE pigs has transformed the field of
xenotransplantation and rejuvenated the hopes for clinical
xenotransplantation. However, there are parts of this puzzle
that still need to be solved.10,11 Some of the major obstacles,
after overcoming the Gal antibody barrier, include the
presence of preformed and elicited non-Gal antibodies
against multiple antigens,12 consumptive coagulopathy1110 The Journal of Thoracic and Cardiovascular Surcaused by rapid depletion of platelets,13 and TM due to an
induced hypercoagulable state.14
Our laboratory, in collaboration with other groups, has
made several inroads in this field. Conventional immuno-
suppression has been tried in this model, and these agents
reasonably prolonged the graft survival.15,16 We have tried
to improve on the conventional immunosuppression with
the use of target-specific immunosuppressive agents, which,
along with the use of newly available GE pigs, have signif-
icantly improved the graft survival of pig cardiac xenografts
in baboons.
The first step toward improvement in graft survival was
observed with B-cell depletion via anti-CD20 mAb. The
possible mechanisms of depletion include direct lysis via
natural killer cells/macrophages, antibody-mediated cell
cytotoxicity, and complement-dependent cytotoxicity.17
Only 4 doses of anti-CD20 mAb on days 7, 0, 7, and 14
were able deplete the B-cell population for 2 months. The
research group at the Mayo Clinic (Rochester, Minn) has
shown that 1 dose can deplete circulating B cells effectively,
but 4 doses are required to deplete B cells from the
lymphoid organs (Gerry Byrne, personal communication,
October 2011). Although this anti–B-cell treatment was
not effective for plasma cell depletion, because plasma cells
do not express CD20, the levels of both anti–non-Gal IgM
and IgG remained at very low levels because of this treat-
ment, and signs of antibody-mediated rejection were not
seen in any animals receiving anti-CD20 mAb treatment.
Of note, we have reported that the cardiac xenografts do
show some minor deposition of anti–non-Gal antibodies.6
There was a moderate increase in non-Gal antibody levels
after 60 days of survival, but no obvious signs of rejection
were observed. Perhaps the xenograft is ‘‘accommodated’’
by this time or a state of ‘‘immune tolerance’’ is induced.
Currently, studies are being performed to evaluate these
mechanisms. There may be a benefit of continuous
suppression of B cells by anti-CD20 antibody beyond 60
days. The anti-CD40 antibody used in these experiments
also suppresses the B-cell response and may be sufficient
to keep the B-cell response under control after 60 days.
The costimulation blockade pathway was critical to graft
survival, because suppression of this pathwaymodulates the
response of both B and T cells. In the initial experiments, we
targeted the CD40-CD40Ligand pathway by using anti-
CD154 mAb, which yielded the previous longest cardiac
xenograft survival of 236 days. The use of this antibody
in some cases, because of expression of CD154 on platelets
and binding of anti-CD154 to the platelets resulting in their
activation and aggregation, was accompanied by fatal
coagulopathies leading to euthanasia or death of recipient
baboons before graft rejection.6,18 This is a known
complication of this antibody, and as a result anti-CD154
mAb is not recommended for clinical use.19,20 However,
the experiments with this antibody demonstrated thegery c September 2014
FIGURE 3. Complete blood counts: A,WBC count, (B) platelet counts, (C) hematocrit percentage, and (D) hemoglobin levels were compared among all 4
experimental groups.Horizontal bars indicate themedianvalue that is also shown on the graph.HCT, Hematocrit;HGB, hemoglobin;WBC, white blood cell.
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Xbeneficial effect of costimulation blockade in suppressing
the xenogeneic immune response and extending xenograft
survival. The use of anti-CD40 mAb allowed blockade
of the same CD40-CD40L costimulation pathway withoutThe Journal of Thoracic and Carencountering the complications of thrombosis. Two
available anti-CD40 mAbs were used for this purpose,
one generated in mouse (clone 3A8) and one in recombinant
mouse-rhesus chimeric antibody (clone 2C10R4). Neitherdiovascular Surgery c Volume 148, Number 3 1111
FIGURE 4. Graft histology: Hematoxylin–eosin staining of a biopsy sam-
ple from one representative long-term surviving graft each from groups A
(A) and D (B) is shown.Most of the group A graft shows fibrosis with some
areas of normal myocytes, whereas mostly normal myocytes along with a
small area of fibrosis is evident in group D.
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the anti-CD154 mAb (5C8). The antibody from the 3A8
clone was not able to extend graft survival beyond 28
days.9 However, the graft survival was significantly
prolonged with the 2C10R4 clone, irrespective of the pig
genetics used. A higher dose of this antibody was required
in these experiments to produce consistent long-term graft
survival, perhaps because of lower affinity of this antibody
for baboon cells. We also observed a quicker recovery
time from surgery in groups using anti-CD40 mAb.
No complications were observed in groups C or D. A
humanized form of anti-CD40 antibody is under production
and will be available for clinical use soon (Keith Reimann,
personal communication, April 2014).
Additional donor pig genetic modifications used, in addi-
tion to alpha Gal knockout, were transgenic expression of
human CD46 and TBM. Our results indicate that TBM
expression and anti-CD40 treatment were crucial in long-
term graft survival. TBM expression successfully avoided
TM and other coagulation issues. It is difficult to dissect
the preferential role of either of the 2 modifications used,
and further experiments are required for this clarification.
Infections were rarely seen in our animals despite the
long-term infusion of maintenance drugs via a jugular cath-
eter. More complications were related to technical problems
with the tether system than the recipient baboon themselves.
No perioperative graft dysfunction was observed. Some pig
viruses, such as cytomegalovirus (CMV), have been shown
to affect graft survival in pig allograft models, but we have
not seen any active CMV disease in any of our baboons
except 1 in which CMV inclusion bodies were found in
the testes on necropsy. The source of these inclusion bodies
was not determined, and no evidence of active CMV disease1112 The Journal of Thoracic and Cardiovascular Surwas found in this baboon. Other complications experienced
over the length of the project included abdominal bleeding,
gastrointestinal bleeding, aspiration pneumonia, seizures,
thrombocytopenia, and anemia.21
Additional technical improvements contributed favor-
ably to aiding graft survival. Video and telemetric moni-
toring allowed early identification and management of
complications expeditiously.22 For example, infections
were detected early by monitoring recipient temperature
via telemetry. Video monitoring allowed continuous sur-
veillance of the baboons and triggered prompt response to
emergencies such as infusion pump malfunction, tether/
jacket problems, and seizures. These methods retrospec-
tively enabled us to evaluate the onset of any complication.
CONCLUSIONS
Significant improvement in graft survival from 179
days23 to 8 months,8 and to more than 1 year as we reported,
by using newly available GE pigs and an immunosuppres-
sion regimen based on an nonhuman primate-mouse
chimeric anti-CD40 mAb (2C10R4), along with the
histology showing preservation of heart architecture in
long-term grafts, is encouraging and indicates that these
xenograft hearts can be tested in the orthotopic position
for their ability to sustain life.
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XDiscussion
Dr Joren Madsen (Boston, Mass). I congratulate the speaker
and the Society for recognizing the importance of this work.
Enthusiasm in xenotransplantation has waxed and waned over
the last 20 years. Dr Shumway used to say, half jokingly but half
seriously, that xenotransplantation was the future of heart
transplantation and always would be. However, these compelling
new findings suggest that the future of xenotransplantation may
be closer than we all thought. Indeed, achieving a greater than
500-day survival of a pig heart in a discordant baboon recipient
sets a new standard for the field and allows us to begin thinking
about human application again.
My major concern in reading your article was your use of the
heterotopic heart transplant model in which the heart graft is not
life sustaining and graft survival times can be easily overestimated.
However, your use of the innovative telemetry techniques to
continuously monitor intracardiac pressures has temperedThe Journal of Thoracic and Carthose concerns. I have 3 questions that relate to your recipients in
group D.
What was the specific immune or nonimmune mechanism that
led to the loss of 2 of the 5 recipients in group D? Will additional
immunotherapeutics or genetic modifications be required to
achieve 100% survival?
Dr Mohiuddin. The 2 animals that rejected in group D were
explanted. One of them had long-term fever with no cause to be
found, and because of strict animal care rules, we had to euthanize
this animal. This animal showed no significant necropsy finding
but had some inclusion CMV bodies in its testes. There was no
evidence of any active CMV disease in this animal. The other
animal that we explanted had repeated episodes of ventricular
fibrillation, and we took the heart out to satisfy our Animal Care
and Use Committee concerns.
In both these hearts, we did see a lot of fibrosis and myocyte
damage on histology, but there were areas preserved that had
normal myocardium. It is hard to pinpoint the exact cause of rejec-
tion, and all these animals had high levels of antibodies against
non-GAL antigens. It is possible that both the antibody and the
TM played significant roles in the delayed rejection of these hearts.
Additional expression of human genes to avert TM and careful
adjustment of anti-CD40 dose may yield an even better survival.
Dr Madsen. Many investigators believe that successful xeno-
transplantation will require the induction of immune tolerance.
Do you believe or have any evidence that your protocol resulted
in immune tolerance, and if so, would you consider weaning all
drugs at a certain time point to limit the morbidity and mortality
related to chronic immunosuppression?
Dr Mohiuddin. In one of the animals, which has survived for
approximately 600 days now, we have done some preliminary
studies. We have done mixed lymphocyte reaction assays from
the lymphocytes and saved cells from the donor pig, and we
have seen that this animal was hyporesponsive to the donor-spe-
cific antigen. But when we tested responses against cells from a
third-party pig, these cells were responsive. So there is an element
of ‘‘tolerance’’ in there, but we need to do a lot more studies to
evaluate that. We have already started to taper the immunosuppres-
sive drugs in 2 of 3 surviving animals. In explanted grafts, we have
found no evidence of chronic vasculopathy.
Dr Madsen. The last question concerns infections. Other have
found that reactivation of pig and even baboon CMV seems to have
serious adverse effects in pig-to-baboon xenotransplantation.
Given your exclusive use of SPF animals, are you concerned that
the same excellent results may not be achieved in non-SPF animals
or, for that matter, in humans?
Dr Mohiuddin.We tested the levels of the non-Gal antibodies
in SPF baboons, and they were found to be comparable to levels
found in humans. As far as the antibody levels, we are satisfied
with what we have, but I fully acknowledge your concern for
CMV. Although we have not seen active CMV disease in any of
our animals, the literature shows that this is a big concern, and
we will have to keep a close eye on that.
Dr Madsen. Thank you and congratulations.
Dr R. Duane Davis (Durham, NC). This is an interesting series
of experiments. Let me follow up a little bit on what Joren was
asking in terms of the antibody-mediated rejection assessment
on the organs that are still working. Have you been followingdiovascular Surgery c Volume 148, Number 3 1113
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Xthe anti-swine antibody titers? You mentioned you started with
low-titer baboons as recipients. How low were they? What has
happened over the period of time in terms of the development of
anti-pig, non-GAL antibodies?
Dr Mohiuddin. As I mentioned earlier, the non-Gal antibody
levels in SPF baboons are lower than in the conventional baboons
and comparable to the levels in humans. The levels vary from ba-
boon to baboon. We give 4 doses of rituximab that completely
takes care of B cells, and these B cells do not return until day
60. After that period, we do see somewhat higher titers of anti-
bodies than their baseline levels. In the earlier groups, we did
find antibody deposition in the heart, but what role they are playing
is not evident.
DrDavis.When you say by using that dose you are clearing
all of the B cells, are you looking at the B1 cells in the peri-
toneal cavity, and along those lines are you looking at the cen-
tral compartment? Obviously, you have plasma cells and some
of the other long lines that antiCD20 does not actually
address.
DrMohiuddin. Exactly, that is our concern also, because CD20
does not take care of plasma cells, people have shown the role of
bortezomib in eliminating plasma cells, which we have not tried. A
single dose of rituximab can eliminate the peripheral circulating B
cells. But what we have shown earlier, and Chris McGregor’s
group, is that you need at least 4 doses to completely wipe out B
cells in all compartments.
Dr Y. Joseph Woo (Philadelphia, Pa). Do the standard xeno-
transplantation models entail continuous heparin anticoagulation?1114 The Journal of Thoracic and Cardiovascular SurDr Mohiuddin. Yes, and we have seen a beneficial effect of it.
We keep these animals on tether and continuous heparin infusion.
Dr Woo. Among the prior models that yielded survival only up
to 500 days, did these involve anticoagulation? How much is the
anticoagulation benefiting your model?
DrMohiuddin.Wemonitor their ACTand try to keep the level
twice the level of the baseline number, and we maintain it
throughout. Others have tried various forms of anticoagulation
for variable periods of time; some of them have tried for a few
months and others for only a few weeks. We are the only ones, I
think, who have used it on a continuous basis.
Dr Woo. So it may be contributing significantly?
Dr Mohiuddin. Definitely.
Dr Woo. In this heterotopic model, can the grafts undergo an
endovascular endomyocardial biopsy?
Dr Mohuddin. Yes, the histology results I showed in my pre-
sentation are the 1-year biopsy results from our long-term graft.
Dr Woo. They weren’t the final pathology?
DrMohiuddin. The long-term graft results were biopsy results,
but for the other groups, we have explanted the heart, and the re-
sults shown are from the final pathology.
DrWoo. Did you ever modify the anti-rejection regimen on the
basis of biopsy findings?
Dr Mohiuddin. Not really, because the major problem is the
antibodies in xenotransplantation. Our main goal is to first tackle
the antibody and the molecules that are incompatible with this
model. We do initiate rescue therapy with steroids when we see
onset of rejection, but this therapy has not helped us so far.gery c September 2014
